A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results . Following the re-organisation of the NHS these drugs are commissioned by:
NHS National Tariff Payment System for 2023 to 2025 is available here
A summary of PbR excluded from tariff drugs commissioned by ICB or NHSE is available here (2023-24)
A detailed list of medicines directly commissioned by NHS England is available here - (Version 18. 2023-24)
NHS England are the responsible commissioners for the management of the Cancer Drugs Fund. For details of the CDF click here
A list of technologies with approved Patient Access Schemes is available here
The Manual - this is a technical document describing the prescribed specialised services, some of these are directly commissioned by NHS England and some by ICBs
Commissioning intentions - this serves as notice to all providers of specialised services in England of changes and priorities for the coming year
A significant proportion of high cost drugs excluded from tariff are commissioned by Derbyshire in line with NICE Technology Appraisals.
Biologic algorithms for use across Derbyshire are listed below:
Speciality |
Last updated |
Cardiology | |
Primary hypercholesterolaemia and mixed dyslipidaemia | May 2023 |
Dermatology | |
Atopic Dermatitis |
September 2022 |
Psoriasis |
August 2023 |
Gastroenterology |
|
Crohn's Disease |
July 2023 |
Ulcerative Colitis |
January 2023 |
ITP | |
Chronic immune (idiopathic) or refractory chronic thrombocytopenic purpura | April 2023 |
Neurology | |
Migraine | August 2023 |
Sodium oxybate | May 2023 |
Ophthalmology | |
Age-Related Macular Degeneration (ARMD) | July 2022 |
Diabetic Macular Oedema (DMO) | September 2022 |
Macular Oedema due to BRVO/CRVO | January 2020 |
Non-Infectious Posterior Uveitis | May 2023 |
Osteoporosis | |
Romosozumab | July 2022 |
Rheumatology | |
Ankylosing Spondylitis | March 2023 |
Psoriatic Arthritis | September 2022 |
Moderate Rheumatoid Arthritis | August 2021 |
Severe Rheumatoid Arthritis | April 2021 |